Newsletter | December 4, 2023

12.04.23 -- Drug Delivery Systems: Measurement System Analysis


Drug Delivery Systems: Measurement System Analysis, Part 1

All drug delivery manufacturing systems undergoing quality improvement involve teams to gather inputs and analyze the data. This article, the first in a series, provides an overview and theoretical understanding of measurement system analysis using continuous gage repeatability and reproducibility (R&R) studies.


Microencapsulation For Drug Bioavailability And Taste Masking

Formulating drugs today is becoming increasingly challenging due to a variety of factors. Enter microencapsulation, a process that offers several advantages for pharmaceutical applications.

Diagnose Absorption Risks To Improve Preclinical And Clinical Outcomes

Physiologically based pharmacokinetic modeling is a powerful tool for clinical trial design that can be leveraged alongside early development experiments to reduce costs and accelerate timelines.

Applying Automation To The Manufacture Of Drug Delivery Devices

Automated manufacturing is a powerful but often-misunderstood tool available to produce drug delivery and other pharmaceutical devices — whether established designs or innovative new ideas.

Preclinical Swine Model Of Large Volume Subcutaneous Injection Pressure Predictive And Translational To Clinical Human Model

The transition of intravenous in-clinic chronic disease therapies to large volume subcutaneous injections in alternate settings has created an evolving roster of new formulations and treatment options.

Formulation Development For Injectables

A uniquely modified cyclodextrin is emerging as a versatile and indispensable tool for development. Explore how the right formulation approach can enhance drug delivery and improve patient outcomes.

Selective Crystallization Of A Novel Polymorph

Discover how applied rigorous characterization standards and expert knowledge of critical water activity enabled the isolation of a previously undiscovered and uncharacterized polymorph.

How Lipid Nanoparticles Overcome Solubility Challenges

More than 80% of NCEs are poorly soluble compounds. Overcoming this challenge using lipid nanoparticles is essential to move your drug product through the pipeline and into the market.

CDMOs Step Up Parenteral Manufacturing Support

Jeff Clement, executive director, CDMO business development North America, discusses the impact of the pandemic on CDMOs and parenteral market trends.


Inhaled Product Development

Providing Better Filling Solutions For Your Injectable Drug Product

Combination Products

IV Solution Expansion